Clinical Trial Update: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of fulvestrant and ipatasertib in advanced ER-positive, HER2-negative breast cancer after progression on a first-line…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-28